What Immunovant, Inc. does.

Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies.

We believe that FcRn inhibition has broad therapeutic and commercial potential to address pathogenic IgG-mediated autoimmune diseases in several therapeutic areas, including but not limited to, endocrinology, neurology, rheumatology and dermatology. Third-party estimates suggest over four million patients in the United States and Europe could benefit from anti-FcRn treatments across more than 20 indications that have been publicly announced for research and development by multiple companies, with two indications that are already approved and launched quickly reaching multi-billions of dollars in global annual sales.

Revenue and profit, by fiscal year.

More on IMVT.

• Immunovant, Inc. summary
• Immunovant, Inc. financial statements
• Immunovant, Inc. key metrics
• Immunovant, Inc. health scores and style box
• Immunovant, Inc. earnings
• Immunovant, Inc. dividends
• Immunovant, Inc. valuation
• Immunovant, Inc. ownership and insiders
• Immunovant, Inc. peers

Figures from Immunovant, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.